Pancreatic Cancer Research

ResearcherJiangnan UniversityActive in the last 2 years

Yongping Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1685-0491; OpenAlex author ID A5101843170. Sources: OpenAlex.

Their work

Papers
16 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2018: 5 papers · 2019: none · 2020: 2 papers · 2021: none · 2022: none · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers · 2026: 3 papers

Papers 16

  1. CT-based Node-RADS for evaluating regional lymph node metastasis and postoperative recurrence in patients with pancreatic ductal adenocarcinoma undergoing upfr… Co-author DOI 10.1007/s00330-026-12564-x↗
  2. CT-derived body composition predicts futile upfront resection in pancreatic cancer: a multicenter study. First author DOI 10.1007/s00330-026-12643-z↗
  3. Comparison of Node-RADS for regional lymph node metastasis in pancreatic ductal adenocarcinoma via CT and MRI. Co-author DOI 10.1016/j.ejrad.2026.112879↗
  4. Combination of imaging features on pancreatic CT for predicting early recurrence after upfront pancreatoduodenectomy of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ejro.2025.100672↗
  5. Bibliometric analysis of global research trends in pancreatic cancer immunotherapy. Co-author DOI 10.1080/21645515.2025.2538330↗
  6. Retraction Note: Upregulation of ARHGAP30 attenuates pancreatic cancer progression by inactivating the β-catenin pathway. Co-author DOI 10.1186/s12935-025-03710-4↗
  7. Exosomal SOX21-AS1 Regulates EREG by Sponging miR-451a and Promotes the Malignancy of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.7150/jca.95014↗
  8. A CT Radiomics-Based Risk Score for Preoperative Estimation of Intraoperative Superior Mesenteric-Portal Vein Involvement in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-022-12664-0↗
  9. ASO Author Reflections: Estimation of Intraoperative Superior Mesenteric-Portal Vein Involvement in Pancreatic Ductal Adenocarcinoma on Preoperative CT-Radiomi… Co-author DOI 10.1245/s10434-022-12713-8↗
  10. Upregulation of ARHGAP30 attenuates pancreatic cancer progression by inactivating the β-catenin pathway. Co-author DOI 10.1186/s12935-020-01288-7↗
  11. Radiomics-Assisted Presurgical Prediction for Surgical Portal Vein-Superior Mesenteric Vein Invasion in Pancreatic Ductal Adenocarcinoma. First author DOI 10.3389/fonc.2020.523543↗
  12. LncRNA UCA1 impacts cell proliferation, invasion, and migration of pancreatic cancer through regulating miR-96/FOXO3. Co-author DOI 10.1002/iub.1699↗
  13. Study on mechanism about long noncoding RNA MALAT1 affecting pancreatic cancer by regulating Hippo-YAP signaling. Co-author DOI 10.1002/jcp.26357↗
  14. Prognostic role of the neutrophil-to-lymphocyte ratio in pancreatic cancer: A meta-analysis containing 8252 patients. Co-author DOI 10.1016/j.cca.2018.01.024↗
  15. The long coding RNA AFAP1-AS1 promotes tumor cell growth and invasion in pancreatic cancer through upregulating the IGF1R oncogene via sequestration of miR-133… Co-author DOI 10.1080/15384101.2018.1496741↗
  16. Prognostic value of platelet-to-lymphocyte ratio in pancreatic cancer: a comprehensive meta-analysis of 17 cohort studies. Co-author DOI 10.2147/ott.s154162↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Fang‐Ming Chen · 8 shared papers, 2020–2026 · strength 2.04
  2. Xiangpan Meng · 3 shared papers, 2026 · strength 0.95
  3. Zhiyuan Hua · 6 shared papers, 2018–2025 · strength 0.86
  4. Jing Xu · 2 shared papers, 2026 · strength 0.67
  5. Tu Dai · 3 shared papers, 2020–2025 · strength 0.60
  6. Gui-Xue Dai · 2 shared papers, 2025–2026 · strength 0.55
  7. Liying Wang · 3 shared papers, 2018–2025 · strength 0.47
  8. Hao Wang · 2 shared papers, 2023–2025 · strength 0.46
  9. Yong Yan · 2 shared papers, 2023–2024 · strength 0.40
  10. Jian Zhang · 1 shared paper, 2025 · strength 0.27
  11. Tong Fu · 1 shared paper, 2025 · strength 0.27
  12. Shuanglin Zhang · 1 shared paper, 2025 · strength 0.27
  13. Xu Zhang · 1 shared paper, 2025 · strength 0.27
  14. Bin Xu · 1 shared paper, 2024 · strength 0.21
  15. Haixin Qian · 2 shared papers, 2018 · strength 0.19
  16. Lei Zhang · 1 shared paper, 2020 · strength 0.13
  17. Yongzhao Zhao · 1 shared paper, 2018 · strength 0.11
  18. Tu Dai · 1 shared paper, 2018 · strength 0.09
  19. Tu Dai · 1 shared paper, 2018 · strength 0.09
  20. Bo Chen · 1 shared paper, 2018 · strength 0.09
  21. Yongkun Wang · 1 shared paper, 2018 · strength 0.08
  22. Xiaohua Jiang · 1 shared paper, 2018 · strength 0.08
  23. Bo Chen · 1 shared paper, 2018 · strength 0.08
  24. Wujun Xiong · 1 shared paper, 2018 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.